专栏名称: 闲谈Immunology

沟通免疫学基础研究与产业化！

海内外大咖纷至沓来，Global XDC 2024嘉宾阵容首发！

闲谈Immunology · 公众号 · · 2024-08-15 08:16

正文

2023年，全球ADC领域发生了20多起并购和合作授权交易，ADC和偶联药的市场达到了空前的热潮。中国本土药企在ADC重磅交易的大潮中表现亮眼，展示了本土药企在新药研发领域的技术创新实力。据沙利文披露的数据显示，截至2023年12月，全球已有超过200款ADC分子处于临床开发阶段。临床新靶点的数量也创历史新高，HER2、TROP2传统靶点热度不减，而新靶点HER3、Claudin18.2、EGFR也在临床中展现出了显著的疗效。

2024年ADC领域的火爆仍在继续，多个ADC Biotech被MNC并购，行业热度只增不减，2024被视为是持续高速发展的时期。 第三届生物偶联药全球创新峰会（Global XDC2024） 将于今年9月再次在中国无锡举行，由药明合联和佰傲谷BioValley共同主办。大会以“ 探索偶联药的无限可能 ”为主题，将聚焦于 新靶点发现与验证 、 ADC和新型偶联药物创新技术 、 载荷-连接子新技术 ，以及 CMC挑战和商业化策略 等内容，引领ADC开发新范式。

本届峰会邀请了众多生物偶联药领域的国际专家与会，共同探讨创新合作，碰撞思想，助力生物偶联药行业蓬勃发展。

Global XDC 2024

国际阵容强势来袭

聆听生物偶联药的世界声音

Jimmy Li

CEO, WuXi XDC

John Zhu

Founder and CEO, Duality Biologics

SJ Lee

CEO, Orum Therapeutics

Topic: Protein Homeostasis by Dual-precision Targeted Protein Degradation and Stabilization

Ben Ayers

VP of ADC Platforms, Hummingbird Bioscience

Topic: A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs

Brian Fiske

Co-Founder and CSO, Mythic Therapeutics

Topic: MYTX-011: A cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression

Pini Tsukerman

Co-Founder and CSO, Nectin Therapeutics

Topic: NTX1105: Best-In-Class ADC targeting Nectin-4

Stefan Hart

Senior Director of Scientific Innovation Oncology, Janssen

Topic: Collaborating within the global life science ecosystem to advance breakthrough science

Marie Zhu

CTO, WuXi XDC

Barbara Valsasina

Head of ADC portfolio, Nerviano Medical Sciences

Topic: Next generation ADCs:novel targets, payloads, linkers and conjugation technologies

Sung-Ju Moon

CSO, IntoCell, Inc.

Topic: Nexatecan™: OHPAS-able Topo1 inhibitor for ADC

Hyun Yong Cho

CSO, Pinotbio, Inc.

Topic: Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, and dual payload system

Hsing-Mao Chu

CEO, T-E Meds, Inc.

Topic: Versatile Drug Bundle-Based ADC Platform: Achieving Site-Specific Conjugation, DAR of 8 or 12, and Dual Payloads

Jing Li

Founder, Chairman and CEO, VelaVigo

Zaiqi Wang

Chairman and CEO, Inxmed

Mao Yin

Founder and CSO, PrimeLink Bio

Jianxin Yang

CEO, President of R&D, CStone Pharmaceuticals

Topic: CS5001, a potential best-in-class ROR1 ADC

Bo Shan

CEO, BoomRay

Topic: RDC-the exploration of New Drug Modality in unmet clinical need

Kanaga Sabapathy

Ph.D, FRCPath, Professor and Chair, NTU

Topic: INTRA-CELLULaR MUTANT EPITOPES – NOVEL TARGETS FOR ADC and BISPECIFIC ANTIBODIES?

Yi Yang

VP and CSO, Biocytogen

Liang Chen

CEO and Co-founder, Great Bay Bio Limited

Topic: GBB’s AI-enabled Ecosystem Elevating Biological Drug Development

Tao Xu

Founder and CEO, SmartNuclide

Sang Jeon Chung

CSO, AbTis Co. Ltd.

Topic: AT211: CLDN18.2-targeting ADC prepared by AbClick Pro

Gary Khoo

VP for CMC, Hummingbird Bioscience

Topic: CMC scale-up challenges & COGs for site specific ADCs

Gang Qin

Founder, Chairman&CEO, Quantum Healthcare

Mingde Xia

Founder, Chairman and CEO, Innolake Biopharm

Aidong Qu

CSO, Shanghai Institute of Biological Products co.,LTD.

Ying Qin

Founder, Chairman and CEO, LaNova Medicines

Zhaoyuan Chen

海内外大咖纷至沓来，Global XDC 2024嘉宾阵容首发！

正文

请到「今天看啥」查看全文